New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology’s annual meeting May 29-31, including: Adaptimmune, Affimed, Agios, Alligator, Allogene, Alteogen, Alx, Amgen, Amphivena, Arvinas, Astrazeneca, Athenex, Autolus, Aveo, Bayer, Beigene, Bio-Path, Boundless, Briacell, Bridgebio, Cardiff Oncology, Celltrion, Cytomx, Daiichi, Deciphera, Effector, Eisai, Foundation Medicine, Genocea, Gilead, Gossamer, Harpoon, Heat Biologics, Immunogen, Iovance, IMV, Karyopharm, Kiadis, Kura, Marker, Merck KGaA, Merck, Nextcure, Novartis, Oncolytics, Pfizer, Regeneron, Rgenix, Sanofi, Seattle Genetics, Servier Silverback, Takeda, TG, Tolero, Trillium, Ziopharm.